SCHEMBL10144037

SCHEMBL10144037

Cc1cc(Cl)ccc1OCC=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
HIF1A Q16665 1/20 0.50
TP53 P04637 1/20 0.50
ALOX15 P16050 1/20 0.50
ALDH1A1 P00352 1/20 0.49
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
HPGD P15428 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TSHR P16473 2/20 0.48
NPC1 O15118 1/20 0.48
GAA P10253 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
SCN4A P35499 2/20 0.48
MAPT P10636 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29863367 1.00 KDM4E (0.50) KDM4ECYP1A2CYP2C9HIF1ATP53
SCHEMBL25267589 0.83 KDM4E (0.58) KDM4ECYP1A2CYP2C9HIF1ATP53
SCHEMBL13777342 0.82 TSHR (0.58) KDM4ECYP1A2CYP2C9HIF1ATP53
SCHEMBL2553310 0.81 L3MBTL1 (0.45) KDM4ETP53ALDH1A1LMNASMN1; SMN2
SCHEMBL3736949 0.81 TDP1 (0.56) SMN1; SMN2HPGDTSHRGAAHTT
SCHEMBL22557984 0.81 KDM4E (0.57) KDM4ECYP1A2CYP2C9HIF1ATP53
SCHEMBL11229698 0.79 SCN4A (0.46) KDM4ECYP1A2CYP2C9HIF1ATP53
SCHEMBL29863189 0.79 MRGPRX4 (0.47) CYP2C9ALDH1A1LMNAHPGDMEN1
SCHEMBL5000471 0.79 KDM4E (0.48) KDM4ETP53ALOX15ALDH1A1LMNA
SCHEMBL3728298 0.78 ALDH1A1 (0.49) KDM4ECYP1A2CYP2C9TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS BIOMARIN PHARMACEUTICAL INC. 2012-04-26 US disclosed
EP-1944173-A1 Ink composition and inkjet recording method using the same FUJIFILM Corporation (JP) 2008-07-16 EP disclosed
US-4090861-A Herbicidal 1,3-oxathiolan-5-ones SHELL OIL COMPANY (US) 1978-05-23 US disclosed
US-4062670-A 4-OXAZOLIDONES OR THIAZOLIDONES SHELL OIL COMPANY (US) 1977-12-13 US disclosed
US-4019892-A 2-PHENOXYMETHYL-1,3-OXAZOLIDIN-4-ONE DERIVATIVES SHELL OIL COMPANY (US) 1977-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS ENGASE, GALNT1, GALNT13 KDM4E 3708/4885CYP1A2 2063/4885CYP2C9 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.